Ticagrelor Newbury approved by the Norwegian Health Authorities
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Newbury Pharmaceuticals is pleased to announce the Marketing Approval (MA) of Ticagrelor Newbury in Norway as the first country in a Scandinavian registration procedure. Approvals in Denmark and Sweden are expected to follow upon finalized national reviews.
Ticagrelor is used together with aspirin (acetylsalicylic acid) to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes. It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and unstable angina (a severe type of chest pain). Ticagrelor is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event. The medicine is only available on prescription.
The originator “Brilique”, marketed by AstraZeneca, is estimated to generate annual sales of app. 19 MEUR (source: DLMI Nordic Pharma Insights) across Scandinavia and launch of Ticagrelor Newbury is planned for 2025.
“We are pleased to see our portfolio of products being approved by the Health Authorities. The approval of Ticagrelor Newbury is our second product approval with additional product approvals expected during the year”, says Lars Minor - CEO, Newbury Pharmaceuticals.